One-liner#

Heart failure management requires distinguishing HFrEF (EF ≤40%, treat with GDMT for mortality benefit) from HFpEF (EF ≥50%, focus on symptom control and comorbidities), with diuretics for congestion, daily weights for monitoring, and clear action plans for decompensation.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

Heart failure is a clinical syndrome of symptoms (dyspnea, fatigue, edema) and signs (JVD, crackles, S3) caused by structural or functional cardiac abnormality, resulting in reduced cardiac output or elevated filling pressures.

Classification by ejection fraction:

• HFrEF (Heart Failure with Reduced EF): EF ≤40%; systolic dysfunction; responds to GDMT
• HFmrEF (Mildly Reduced EF): EF 41-49%; may benefit from HFrEF therapies
• HFpEF (Preserved EF): EF ≥50%; diastolic dysfunction; limited proven therapies

NYHA Functional Classification:

• Class I: No limitation; ordinary activity does not cause symptoms
• Class II: Slight limitation; comfortable at rest; ordinary activity causes symptoms
• Class III: Marked limitation; less than ordinary activity causes symptoms
• Class IV: Symptoms at rest; unable to carry on any activity without symptoms

ACC/AHA Stages:

• Stage A: At risk (HTN, DM, CAD) without structural disease or symptoms
• Stage B: Structural disease (prior MI, LVH, low EF) without symptoms
• Stage C: Structural disease with current or prior symptoms
• Stage D: Refractory symptoms requiring advanced therapies

Epidemiology#

Prevalence is approximately 6.5 million adults in the US, with 900,000 new cases annually. Lifetime risk is 1 in 5 at age 40. HFpEF accounts for approximately 50% of cases and is increasing. Risk factors include CAD (most common cause), HTN, DM, obesity, valvular disease, cardiomyopathy, and cardiotoxic agents (alcohol, chemotherapy). Five-year mortality is approximately 50% despite treatment. HF is the leading cause of hospitalization in adults over 65.

Pathophysiology#

Mechanism (clinical understanding)#

HFrEF (systolic dysfunction): Myocardial injury (MI, cardiomyopathy, toxins) reduces contractile function. Compensatory neurohormonal activation (RAAS, sympathetic nervous system) initially maintains cardiac output but causes progressive remodeling: LV dilation, fibrosis, and further dysfunction. This is why GDMT targeting neurohormonal activation (ACE-I/ARNI, beta-blockers, MRAs) improves survival.

HFpEF (diastolic dysfunction): LV is stiff and cannot relax properly during diastole. Normal EF but impaired filling leads to elevated filling pressures, pulmonary congestion, and reduced exercise tolerance. Often associated with HTN, obesity, AF, and aging. Neurohormonal blockade less effective because the problem is stiffness, not contractility.

Why patients decompensate:

• Dietary indiscretion (salt/fluid excess)
• Medication non-adherence
• Arrhythmia (especially new AF with loss of atrial kick)
• Infection, anemia, thyroid dysfunction
• Uncontrolled HTN
• Ischemia
• NSAIDs, CCBs (negative inotropes), or other medications

How to explain to patients#

Your heart is a pump that moves blood through your body. In heart failure, the pump is not working as well as it should. There are two main types.

In one type, the heart muscle is weak and does not squeeze strongly enough. The medicines we use help the heart pump better and live longer.

In the other type, the heart muscle is stiff and does not relax well between beats. This makes it hard for the heart to fill with blood. We focus on controlling fluid and treating other conditions like high blood pressure.

When the heart cannot keep up, fluid backs up into your lungs and legs. That is why you feel short of breath and your legs swell. The water pill helps your body get rid of extra fluid.

Clinical presentation#

Characteristic symptoms#

Congestion (backward failure):

• Dyspnea on exertion (most common presenting symptom)
• Orthopnea: ask “how many pillows do you sleep with?”
• Paroxysmal nocturnal dyspnea (PND): waking up gasping 1-2 hours after lying down
• Lower extremity edema, weight gain
• Abdominal bloating, early satiety (hepatic congestion, ascites)
• Bendopnea: dyspnea when bending forward (elevated filling pressures)

Low output (forward failure):

• Fatigue, weakness
• Exercise intolerance
• Cool extremities
• Confusion (in severe cases)
• Decreased urine output

Physical exam findings#

Volume overload signs:

• JVD (>8 cm above sternal angle at 45 degrees)
• Hepatojugular reflux (JVP rises >3 cm with sustained RUQ pressure)
• S3 gallop (low-pitched, early diastole; indicates volume overload)
• Pulmonary crackles (may be absent in chronic HF due to lymphatic adaptation)
• Peripheral edema (pitting; check sacral edema in bedridden patients)
• Hepatomegaly, ascites

Other findings:

• S4 gallop (late diastole; indicates stiff ventricle, common in HFpEF)
• Displaced PMI (LV dilation)
• Murmurs: MR (functional from LV dilation), TR
• Tachycardia, narrow pulse pressure (low output)
• Cool extremities, delayed capillary refill (low output)

Red flags#

Require urgent evaluation or hospitalization:

• Hypoxia (O2 sat <90% on room air)
• Hypotension (SBP <90) or signs of cardiogenic shock
• New or worsening renal function with congestion (cardiorenal syndrome)
• Syncope or presyncope
• Chest pain (ischemia as precipitant)
• New arrhythmia (especially rapid AF)
• Severe dyspnea at rest
• Weight gain >5 lbs in one week despite adherence
• Altered mental status

Diagnostic workup#

Initial evaluation#

All patients with suspected HF:

• BNP or NT-proBNP: Most useful test to evaluate dyspnea

  • BNP <100 pg/mL or NT-proBNP <300 pg/mL: HF very unlikely
  • BNP >400 pg/mL: HF likely
  • NT-proBNP age-adjusted cutoffs: >450 if <50 yo, >900 if 50-75 yo, >1800 if >75 yo
  • Gray zone: consider echo; may be HFpEF, obesity (lower BNP), renal dysfunction (higher BNP)

• Echocardiogram: Essential for all new HF diagnoses

  • EF: distinguishes HFrEF from HFpEF
  • Wall motion abnormalities (ischemic vs non-ischemic)
  • Valvular disease
  • Diastolic function (E/e’ ratio, LA size)
  • RV function, PA pressure estimate

• ECG: LVH, prior MI (Q waves), arrhythmia, conduction disease

• CXR: Cardiomegaly, pulmonary edema, effusions

• BMP: Baseline Cr, K before starting ACE-I/ARB, diuretics

• CBC: Anemia worsens HF; identify and treat

• TSH: Hyper/hypothyroidism can cause or worsen HF

• Iron studies: Iron deficiency common in HF; treat even without anemia

Confirmatory testing#

Determine etiology (coordinate with cardiology):

• Coronary evaluation: Ischemic cardiomyopathy is most common cause of HFrEF
  • Stress testing or coronary angiography based on clinical suspicion
  • Consider in all new HFrEF without clear non-ischemic cause
• Cardiac MRI: If etiology unclear; identifies infiltrative disease, myocarditis, arrhythmogenic cardiomyopathy
• Right heart catheterization: For hemodynamic assessment in advanced HF or pre-transplant evaluation

HFpEF diagnosis can be challenging:

• EF ≥50% with symptoms and elevated BNP
• Echo shows diastolic dysfunction: elevated E/e’ (>14), LA enlargement, elevated PA pressure
• H2FPEF score helps estimate probability (Heavy, Hypertensive, AF, Pulmonary HTN, Elder, Filling pressure)

When to refer for specialist workup#

Cardiology referral for:

• All new HFrEF diagnoses (GDMT initiation and optimization)
• EF <35% for ICD evaluation
• Suspected ischemic etiology for coronary evaluation
• Refractory symptoms despite optimal therapy
• Consideration for advanced therapies (CRT, LVAD, transplant)
• Uncertain diagnosis (HFpEF vs other causes of dyspnea)

What NOT to order#

• Serial BNP for routine monitoring: Trend is less useful than clinical assessment; use for diagnostic uncertainty, not routine follow-up
• Repeat echo if stable: Only repeat if clinical change or to reassess EF after GDMT optimization (3-6 months)
• Routine Holter in stable HF without arrhythmia symptoms: Low yield
• Endomyocardial biopsy: Rarely indicated; reserve for suspected infiltrative disease or myocarditis when MRI non-diagnostic

Treatment#

Goals of therapy#

HFrEF:

1. Reduce mortality and hospitalizations with GDMT
2. Improve symptoms and functional capacity
3. Achieve euvolemia (dry weight)
4. Prevent disease progression and remodeling

HFpEF:

1. Relieve congestion and symptoms
2. Treat underlying conditions (HTN, AF, CAD, obesity)
3. Improve exercise tolerance
4. Reduce hospitalizations

Targets:

• Euvolemia: no orthopnea, JVD, or edema; at dry weight
• BP <130/80 (or as tolerated on GDMT)
• HR 60-70 on beta-blocker (HFrEF)
• NYHA Class I-II symptoms

Non-pharmacologic management#

Sodium restriction:

• Target <2 g/day (2000 mg)
• Avoid processed foods, canned soups, restaurant meals
• Read nutrition labels; teach patients to identify hidden sodium
• More restrictive (<1.5 g) for refractory congestion

Fluid restriction:

• 1.5-2 L/day if hyponatremic (Na <130) or refractory congestion
• Not routinely needed if euvolemic on diuretics
• Include all liquids: water, coffee, soup, ice

Daily weights:

• Same scale, same time (morning after voiding, before eating)
• Call if gain >2-3 lbs in one day or >5 lbs in one week
• Provides early warning of decompensation before symptoms worsen

Exercise and cardiac rehab:

• Cardiac rehab referral for all stable HF patients
• Improves functional capacity, quality of life, and reduces hospitalizations
• Safe even in HFrEF; start low, progress gradually
• Target 150 min/week moderate activity as tolerated

Other:

• Smoking cessation (essential)
• Limit alcohol (≤1 drink/day; abstain if alcoholic cardiomyopathy)
• Annual influenza and pneumococcal vaccination
• Avoid NSAIDs (fluid retention, worsen renal function)
• Sleep apnea screening and treatment (common comorbidity)

Pharmacologic management#

HFrEF: Guideline-Directed Medical Therapy (GDMT)#

The four pillars of GDMT each independently reduce mortality. Goal is to initiate all four and titrate to target doses.

GDMT initiation strategy:

• Start all four pillars at low doses rather than maximizing one before starting others
• Titrate every 1-2 weeks as tolerated
• Prioritize ARNI and SGLT2i (can start simultaneously)
• Add beta-blocker once euvolemic (not during active decompensation)
• Add MRA when Cr and K stable
• Accept some BP drop if asymptomatic (SBP 90-100 often tolerated)

Additional HFrEF therapies:

HFpEF: Limited Proven Therapies#

HFpEF management priorities:

1. Diuretics for congestion
2. SGLT2 inhibitor (emerging standard of care)
3. Aggressive BP control (<130/80)
4. Rate control for AF (target HR <110)
5. Weight loss if obese (significant symptom improvement)
6. Treat OSA
7. Cardiac rehab

Diuretics (Both HFrEF and HFpEF)#

Diuretic dosing principles:

• Goal is euvolemia (dry weight), not a specific dose
• Adjust based on daily weights, not just symptoms
• If inadequate response: increase dose before adding second agent
• Diuretic resistance: add thiazide (metolazone) for synergy; consider IV diuretics
• In CKD: higher doses needed (furosemide 80-160 mg often required if eGFR <30)

Flexible diuretic dosing (patient self-adjustment):

• Teach patients to adjust diuretic based on weight
• Example: “If weight up 2-3 lbs, take extra 20 mg furosemide; if up >3 lbs, call”
• Requires reliable patient; document specific instructions

Patient counseling points#

For GDMT:

• “These medicines help your heart pump better and help you live longer. Even if you feel fine, keep taking them.”
• “We start at low doses and slowly increase. You may feel tired or dizzy at first—this usually improves.”
• “Do not stop these medicines suddenly. If you have side effects, call us before stopping.”

For diuretics:

• “The water pill helps your body get rid of extra fluid. Take it in the morning so you are not up at night.”
• “Weigh yourself every morning. If you gain more than 2-3 pounds in a day, take an extra water pill and call us.”
• “You may need to urinate more often—this means the medicine is working.”

For lifestyle:

• “Salt makes your body hold onto water. Avoid adding salt and read labels—aim for less than 2000 mg per day.”
• “Weigh yourself every day at the same time. Write it down. This is the best way to catch problems early.”
• “Stay active within your limits. Cardiac rehab is like physical therapy for your heart.”

Monitoring and follow-up#

Initial phase (first 3 months):

• Follow-up every 1-2 weeks during GDMT titration
• Check Cr, K at 1-2 weeks after starting/changing ACE-I/ARB/ARNI or MRA
• Assess volume status, BP, HR at each visit
• Daily weights at home with clear action plan

Stable phase:

• Follow-up every 3-6 months
• Labs: BMP, CBC every 6-12 months; more often if CKD or on MRA
• Repeat echo 3-6 months after GDMT optimization to reassess EF
• Annual influenza vaccination

What to monitor at each visit:

• Weight (compare to dry weight)
• BP, HR
• Volume status: JVD, edema, lung exam
• Functional status: NYHA class, exercise tolerance
• Medication adherence and side effects
• Dietary adherence (sodium, fluid)

Patient education#

What is this condition?#

Your heart is a pump that moves blood through your body. Heart failure means the pump is not working as well as it should. This causes fluid to build up in your lungs and legs.

There are two main types. In one type, the heart muscle is weak. In the other type, the heart muscle is stiff. Both types cause similar symptoms but are treated differently.

Heart failure is a long-term condition. With the right medicines and lifestyle changes, most people can feel better and stay out of the hospital.

What you can do#

Weigh yourself every morning on the same scale. Write it down. Call your doctor if you gain more than 2-3 pounds in one day or 5 pounds in one week.

Eat less salt. Aim for less than 2000 mg per day. Avoid processed foods, canned soups, and fast food. Do not add salt to your food.

Take your medicines every day, even when you feel well. Do not stop any medicine without talking to your doctor first.

Stay active. Walk or do light exercise most days. Cardiac rehab can help you exercise safely.

Limit alcohol. If you drink, have no more than one drink per day.

When to seek care#

Call your doctor if you gain more than 3 pounds in one day or 5 pounds in one week. Call if you feel more short of breath than usual. Call if you have more swelling in your legs or belly. Call if you need more pillows to sleep or wake up short of breath at night.

Go to the emergency room if you have severe trouble breathing. Go if you have chest pain. Go if you feel dizzy or faint. Go if you cough up pink or bloody mucus.

Questions to ask your doctor#

What type of heart failure do I have? What is my heart pumping strength? Am I on all the right medicines? What is my dry weight? What should I do if my weight goes up? When should I call you?

Prognosis and monitoring#

Expected course#

With optimal treatment:

• GDMT in HFrEF reduces mortality by 50-70% compared to no treatment
• Many patients improve to NYHA Class I-II
• EF may improve with GDMT (some patients recover to normal EF)
• Quality of life can be good with adherence

Without treatment:

• Progressive symptoms and functional decline
• Frequent hospitalizations
• High mortality (50% at 5 years overall; worse with lower EF)

Factors associated with worse prognosis:

• Lower EF
• Higher NYHA class
• Elevated BNP
• Renal dysfunction
• Hyponatremia
• Frequent hospitalizations
• Inability to tolerate GDMT

Monitoring parameters#

Complications to watch for#

Arrhythmias:

• AF common (loss of atrial kick worsens symptoms)
• Ventricular arrhythmias (risk of sudden death in HFrEF)
• ICD indicated if EF ≤35% despite 3 months of GDMT

Cardiorenal syndrome:

• Worsening renal function with diuresis
• Accept Cr rise up to 30% if patient improving clinically
• May need to reduce diuretics or GDMT if severe

Worsening HF:

• Recurrent hospitalizations
• Declining functional status
• Consider advanced therapies referral

Medication side effects:

• Hyperkalemia (ACE-I/ARB/ARNI, MRA)
• Hypotension (all GDMT)
• Bradycardia (beta-blockers)
• Worsening renal function (diuretics, ACE-I/ARB)

Special populations#

Elderly/geriatric#

Treatment considerations:

• GDMT still beneficial in elderly; do not withhold based on age alone
• Start at lower doses; titrate more slowly
• More sensitive to hypotension and bradycardia
• Higher risk of falls with diuretics and hypotension
• Polypharmacy: review all medications; deprescribe when possible

Beers criteria considerations:

• Avoid digoxin doses >0.125 mg daily
• Use caution with loop diuretics (electrolyte disturbances, falls)
• Spironolactone: watch K closely; avoid if eGFR <30

Dose adjustments:

• Carvedilol: start 3.125 mg BID; titrate slowly
• Lisinopril: start 2.5 mg daily
• Spironolactone: start 12.5 mg daily; max 25 mg
• Digoxin: 0.0625-0.125 mg daily; target level 0.5-0.9

Goals may differ:

• Prioritize quality of life and symptom control
• Accept higher BP if symptomatic hypotension
• Discuss goals of care; advanced HF may warrant palliative approach

Chronic kidney disease#

Medication adjustments:

Special considerations:

• CKD patients have higher HF mortality; GDMT still beneficial
• Monitor K very closely with ACE-I/ARB + MRA
• Accept Cr rise up to 30% if clinically improving
• Higher diuretic doses needed; may need IV diuretics
• SGLT2i: initial eGFR dip is expected and not harmful; continue unless severe decline

Other populations#

Diabetes:

• SGLT2 inhibitors: dual benefit for HF and diabetes; prioritize in diabetic HF patients
• Metformin: safe in stable HF; avoid in acute decompensation
• Avoid thiazolidinediones (pioglitazone): cause fluid retention and worsen HF
• GLP-1 agonists: CV benefit; safe in HF (neutral effect on HF outcomes)

Atrial fibrillation:

• Common comorbidity (30-40% of HF patients)
• Rate control: beta-blockers preferred in HFrEF; digoxin as adjunct
• Avoid CCBs (diltiazem, verapamil) in HFrEF—negative inotropic effect
• Rhythm control: consider if symptomatic despite rate control; ablation may improve EF
• Anticoagulation: per CHA2DS2-VASc; HF = 1 point

Pregnancy:

• Peripartum cardiomyopathy: HFrEF developing in last month of pregnancy or within 5 months postpartum
• Stop ACE-I/ARB/ARNI (teratogenic); use hydralazine/nitrates
• Beta-blockers: metoprolol, labetalol generally safe
• Diuretics: use cautiously; may reduce placental perfusion
• Requires high-risk OB and cardiology co-management

Polypharmacy considerations:

• NSAIDs: avoid—cause fluid retention, worsen renal function, reduce ACE-I efficacy
• CCBs (non-dihydropyridine): avoid diltiazem/verapamil in HFrEF
• Amlodipine: safe in HF if needed for BP
• Metformin: safe in stable HF
• Thiazolidinediones: contraindicated
• Antiarrhythmics: amiodarone safest in HF; avoid flecainide, propafenone, sotalol

When to refer#

Specialist referral criteria#

Cardiology referral (routine, 2-4 weeks):

• All new HFrEF diagnoses for GDMT optimization
• HFpEF with uncertain diagnosis or refractory symptoms
• Stable HF for device evaluation (ICD, CRT)
• Cardiac rehab referral

Cardiology referral (urgent, within 1 week):

• New HFrEF with EF <35%
• Worsening symptoms despite GDMT
• Recurrent hospitalizations
• New arrhythmia (especially AF with RVR)
• Suspected ischemic etiology requiring coronary evaluation
• Consideration for advanced therapies

Advanced HF/transplant referral:

• Refractory symptoms despite optimal GDMT
• Recurrent hospitalizations (≥2 in 12 months)
• Declining renal function with HF
• Inotrope dependence
• Consideration for LVAD or transplant

Urgency levels#

Smartphrase snippets#

HFrEF, stable on GDMT: HFrEF (EF [X]%), NYHA Class II, euvolemic on GDMT. Weight stable at dry weight; continue current regimen. F/u 3-6 months.

HFrEF, volume overloaded: HFrEF with volume overload: weight up 5 lbs, 2+ edema. Increasing furosemide; recheck BMP in 1 week. F/u 1-2 weeks.

HFpEF, new diagnosis: New HFpEF (EF [X]%, diastolic dysfunction). Started diuretics and SGLT2i; cardiology referral placed. F/u 2-4 weeks.

HF, decompensation: HF decompensation with worsening dyspnea and 8 lb weight gain despite home adjustment. Referred to ED for IV diuretics.

Related pages#

• Edema (complaint) — symptom-based approach to edema including HF as a cause
• Dyspnea on Exertion (complaint) — cardiac vs pulmonary causes of exertional dyspnea
• Chest Pain (complaint) — ischemic cardiomyopathy as cause of HFrEF
• Coronary Artery Disease (problem) — ischemic heart disease is the most common cause of HFrEF
• Atrial Fibrillation (problem) — common comorbidity; AF can precipitate HF decompensation
• Hypertension (problem) — HTN is a major risk factor and cause of HFpEF
• Obstructive Sleep Apnea (problem) — OSA present in 50-75% of HF patients; CPAP may improve symptoms and EF
• COPD (problem) — common comorbidity; overlapping symptoms
• Type 2 Diabetes (problem) — SGLT2 inhibitors benefit both conditions